RÉSUMÉ
PPM1D/Wip1 is a negative regulator of the tumor suppressor p53 and is overexpressed in several human solid tumors. Recent reports associate gain-of-function mutations of PPM1D in immune cells with worse outcomes for several human cancers. Here we show that mice with genetic knockout of Ppm1d or with conditional knockout of Ppm1d in the hematopoietic system, in myeloid cells, or in neutrophils all display significantly reduced growth of syngeneic melanoma or lung carcinoma tumors. Ppm1d knockout neutrophils infiltrate tumors extensively. Chemical inhibition of Wip1 in human or mouse neutrophils increases anti-tumor phenotypes, p53-dependent expression of co-stimulatory ligands, and proliferation of co-cultured cytotoxic T cells. These results suggest that inhibition of Wip1 in neutrophils enhances immune anti-tumor responses.
Sujet(s)
Altération de l'ADN , Immunité , Granulocytes neutrophiles/métabolisme , Protein phosphatase 2C/génétique , Protein phosphatase 2C/métabolisme , Animaux , Antinéoplasiques , Lignée cellulaire tumorale , Prolifération cellulaire , Femelle , Humains , Poumon , Souris , Souris de lignée C57BL , Souris knockout , Phénotype , Lymphocytes T , Microenvironnement tumoral , Protéine p53 suppresseur de tumeur/génétique , Protéine p53 suppresseur de tumeur/métabolismeRÉSUMÉ
Background & Aims: Recent studies have shown that cancers arise as a result of the positive selection of driver somatic events in tumor DNA, with negative selection playing only a minor role, if any. However, these investigations were concerned with alterations at nonrepetitive sequences and did not take into account mutations in repetitive sequences that have very high pathophysiological relevance in the tumors showing microsatellite instability (MSI) resulting from mismatch repair deficiency investigated in the present study. Methods: We performed whole-exome sequencing of 47 MSI colorectal cancers (CRCs) and confirmed results in an independent cohort of 53 MSI CRCs. We used a probabilistic model of mutational events within microsatellites, while adapting pre-existing models to analyze nonrepetitive DNA sequences. Negatively selected coding alterations in MSI CRCs were investigated for their functional and clinical impact in CRC cell lines and in a third cohort of 164 MSI CRC patients. Results: Both positive and negative selection of somatic mutations in DNA repeats was observed, leading us to identify the expected true driver genes associated with the MSI-driven tumorigenic process. Several coding negatively selected MSI-related mutational events (n = 5) were shown to have deleterious effects on tumor cells. In the tumors in which deleterious MSI mutations were observed despite the negative selection, they were associated with worse survival in MSI CRC patients (hazard ratio, 3; 95% CI, 1.1-7.9; P = .03), suggesting their anticancer impact should be offset by other as yet unknown oncogenic processes that contribute to a poor prognosis. Conclusions: The present results identify the positive and negative driver somatic mutations acting in MSI-driven tumorigenesis, suggesting that genomic instability in MSI CRC plays a dual role in achieving tumor cell transformation. Exome sequencing data have been deposited in the European genome-phenome archive (accession: EGAS00001002477).
Sujet(s)
Carcinogenèse/génétique , Tumeurs colorectales/génétique , Instabilité des microsatellites , Mutation/génétique , Séquences répétées d'acides nucléiques/génétique , Animaux , Séquence nucléotidique , Lignée cellulaire tumorale , Études de cohortes , Femelle , Hétérogreffes , Humains , Mâle , Souris , Souris nude , Modèles statistiques ,RÉSUMÉ
Background: Immune checkpoint (ICK) expression might represent a surrogate measure of tumor-infiltrating T cell (CTL) exhaustion and therefore be a more accurate prognostic biomarker for colorectal cancer (CRC) patients than CTL enumeration as measured by the Immunoscore. Methods: The expression of ICKs, Th1, CTLs, cytotoxicity-related genes, and metagenes, including Immunoscore-like metagenes, were evaluated in three independent cohorts of CRC samples (260 microsatellite instable [MSI], 971 non-MSI). Their associations with patient survival were analyzed by Cox models, taking into account the microsatellite instability (MSI) status and affiliation with various Consensus Molecular Subgroups (CMS). PD-L1 and CD8 expression were examined on a subset of tumors with immunohistochemistry. All statistical tests were two-sided. Results: The expression of Immunoscore-like metagenes was statistically significantly associated with improved outcome in non-MSI tumors displaying low levels of both CTLs and immune checkpoints (ICKs; CMS2 and CMS3; hazard ratio [HR] = 0.63, 95% confidence interval [CI] = 0.43 to 0.92, P = .02; and HR = 0.55, 95% CI = 0.34 to 0.90, P = .02, respectively), but clearly had no prognostic relevance in CRCs displaying higher levels of CTLs and ICKs (CMS1 and CMS4; HR = 0.46, 95% CI = 0.10 to 2.10, P = .32; and HR = 1.13, 95% CI = 0.79 to 1.63, P = .50, respectively), including MSI tumors. ICK metagene expression was statistically significantly associated with worse prognosis independent of tumor staging in MSI tumors (HR = 3.46, 95% CI = 1.41 to 8.49, P = .007). ICK expression had a negative impact on the proliferation of infiltrating CD8 T cells in MSI neoplasms (median = 0.56 in ICK low vs median = 0.34 in ICK high, P = .004). Conclusions: ICK expression cancels the prognostic relevance of CTLs in highly immunogenic colon tumors and predicts a poor outcome in MSI CRC patients.
Sujet(s)
Marqueurs biologiques tumoraux/génétique , Marqueurs biologiques tumoraux/immunologie , Tumeurs colorectales/génétique , Tumeurs colorectales/immunologie , Lymphocytes TIL , Lymphocytes T cytotoxiques , Antigènes CD/génétique , Antigène CD274/analyse , Antigène CD274/génétique , Antigènes CD8/analyse , Antigène CTLA-4/génétique , Côlon/composition chimique , Tumeurs colorectales/composition chimique , Tumeurs colorectales/anatomopathologie , Femelle , Expression des gènes , Récepteur cellulaire-2 du virus de l'hépatite A/génétique , Humains , Protéine inductible de costimulation du lymphocyte T/génétique , Mâle , Instabilité des microsatellites , Adulte d'âge moyen , Stadification tumorale , Pronostic , Ligand-2 de la protéine-1 de mort cellulaire programmée/génétique , Récepteur-1 de mort cellulaire programmée/génétique , Études rétrospectives , Taux de survie , Lymphocytes auxiliaires Th1 , Protéine LAG-3RÉSUMÉ
Microsatellite instability (MSI) caused by mismatch repair deficiency (dMMR) is detected in a small proportion of pancreatic ductal adenocarcinomas (PDACs). dMMR and MSI have been associated with responses of metastatic tumors, including PDACs, to immune checkpoint inhibitor therapy. We performed immunohistochemical analyses of a 445 PDAC specimens, collected from consecutive patients at multiple centers, to identify those with dMMR, based on loss of mismatch repair proteins MLH1, MSH2, MSH6, and/or PMS2. We detected dMMR in 1.6% of tumor samples; we found dMMR in a larger proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02). PDACs with dMMR contained potentially immunogenic mutations because of MSI in coding repeat sequences. PDACs with dMMR or MSI had a higher density of CD8+ T cells at the invasive front than PDACs without dMMR or MSI (P = .08; Fisher exact test). A higher proportion of PDACs with dMMR or MSI expressed the CD274 molecule (PD-L1, 8/9) than PDACs without dMMR or MSI (4/10) (P = .05). Times of disease-free survival and overall survival did not differ significantly between patients with PDACs with dMMR or MSI vs without dMMR or MSI. Studies are needed to determine whether these features of PDACs with dMMR or MSI might serve as prognostic factors.
Sujet(s)
Carcinome du canal pancréatique/génétique , Instabilité des microsatellites , Tumeurs kystiques, mucineuses et séreuses/génétique , Tumeurs du pancréas/génétique , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques tumoraux/analyse , Lymphocytes T CD8+/immunologie , Carcinome du canal pancréatique/composition chimique , Carcinome du canal pancréatique/immunologie , Carcinome du canal pancréatique/anatomopathologie , Protéines de liaison à l'ADN/analyse , Survie sans rechute , Femelle , Prédisposition génétique à une maladie , Humains , Lymphocytes TIL/immunologie , Mâle , Adulte d'âge moyen , Mismatch repair endonuclease PMS2/analyse , Protéine-1 homologue de MutL/analyse , Protéine-2 homologue de MutS/analyse , Tumeurs kystiques, mucineuses et séreuses/composition chimique , Tumeurs kystiques, mucineuses et séreuses/immunologie , Tumeurs kystiques, mucineuses et séreuses/anatomopathologie , Tumeurs du pancréas/composition chimique , Tumeurs du pancréas/immunologie , Tumeurs du pancréas/anatomopathologie , Phénotype , Facteurs tempsSujet(s)
Eczéma de contact/immunologie , Protein phosphatase 2C/métabolisme , Peau/immunologie , Animaux , Eczéma de contact/étiologie , Eczéma de contact/anatomopathologie , Souris de lignée C57BL , Souris knockout , Protein phosphatase 2C/génétique , Peau/effets des médicaments et des substances chimiques , 12-Myristate-13-acétate de phorbol/toxicitéRÉSUMÉ
Cells undergoing oncogenic transformation frequently inactivate tumor suppressor pathways that could prevent their uncontrolled growth. Among those pathways p53 and p38MAPK pathways play a critical role in regulation of cell cycle, senescence and cell death in response to activation of oncogenes, stress and DNA damage. Consequently, these two pathways are important in determining the sensitivity of tumor cells to anti-cancer treatment. Wild type p53-induced phosphatase, Wip1, is involved in governance of both pathways. Recently, strategies directed to manipulation with Wip1 activity proposed to advance current day anticancer treatment and novel chemical compounds synthesized to improve specificity of manipulation with Wip1 activity. Here we reviewed the history of Wip1 studies in vitro and in vivo, in genetically modified animal models that support Wip1 role in tumorigenesis through regulation of p53 and p38MAPK pathways. Based on our knowledge we propose several recommendations for future more accurate studies of Wip1 interactions with other pathways involved in tumorigenesis using recently developed tools and for adoption of Wip1 manipulation strategies in anti-cancer therapy.
Sujet(s)
Protein phosphatase 2C/métabolisme , Transduction du signal , Protéine p53 suppresseur de tumeur/métabolisme , p38 Mitogen-Activated Protein Kinases/métabolisme , Animaux , Cycle cellulaire/génétique , Transformation cellulaire néoplasique/génétique , Altération de l'ADN , Humains , Mutation , Protein phosphatase 2C/génétiqueRÉSUMÉ
HSP70 is a chaperone that accumulates in the cells after many different stresses promoting cell survival in response to the adverse conditions. In contrast to normal cells, most cancer cells abundantly express HSP70 at the basal level to resist to various insults at different stages of tumorigenesis and during anti-cancer treatment. This cancer cells addiction for HSP70 is the rational for its targeting in cancer therapy. Much effort has been dedicated in the last years for the active search of HSP70 inhibitors. Additionally, the recent clinical trials on highly promising inhibitors of another stress protein, HSP90, showed compensatory increase in HSP70 levels and raised the question of necessity to combine HSP90 inhibitors with simultaneous inhibition of HSP70. Here we analyzed the recent advancement in creation of novel HSP70 inhibitors and different strategies for their use in anti-cancer therapy.
Sujet(s)
Antinéoplasiques/usage thérapeutique , Protéines du choc thermique HSP70/antagonistes et inhibiteurs , Thérapie moléculaire ciblée , Protéines tumorales/antagonistes et inhibiteurs , Tumeurs/traitement médicamenteux , Animaux , Antinéoplasiques/pharmacologie , Apoptose/physiologie , Autophagie/physiologie , Conception de médicament , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Tests de criblage d'agents antitumoraux , Protéines du choc thermique HSP70/composition chimique , Protéines du choc thermique HSP70/physiologie , Protéines du choc thermique HSP90/antagonistes et inhibiteurs , Humains , Chaperons moléculaires/antagonistes et inhibiteurs , Chaperons moléculaires/physiologie , Protéines tumorales/physiologie , Tumeurs/immunologie , Structure tertiaire des protéines/effets des médicaments et des substances chimiques , Stress physiologiqueRÉSUMÉ
Wip1 is a stress-response phosphatase that negatively regulates several tumor suppressors, including p53. In a sizeable fraction of tumors, overexpression or amplification of Wip1 compromises p53 functions; inhibition of Wip1 activity is an attractive strategy for improving treatment of these tumors. However, over half of human tumors contain mutations in the p53 gene or have lost both alleles. Recently, we observed that in cancer cells lacking wild type p53, reduction of Wip1 expression was ineffective, whereas, surprisingly, overexpression of Wip1 increased anticancer drug sensitivity. The increased sensitivity resulted from activation of the intrinsic pathway of apoptosis through increased levels of the pro-apoptotic protein Bax and decreased levels of the anti-apoptotic protein Bcl-xL. We showed that interaction of Wip1 and the transcription factor RUNX2, specifically through dephosphorylation of RUNX2 phospho-S432, resulted in increased expression of Bax. Interestingly, overexpression of Wip1 increased drug sensitivity only in the p53-negative tumor cells while protecting the wild type p53-containing normal cells from drug-induced collateral injury. Here, we provide evidence that Wip1 overexpression decreases expression of Bcl-xL through negative regulation of NFκB activity. Thus, Wip1 overexpression increases the sensitivity of p53-negative cancer cells to anticancer drugs by separately affecting Bax and Bcl-xL protein levels.
Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Phosphoprotein Phosphatases/métabolisme , Protéine p53 suppresseur de tumeur/métabolisme , Protéine Bax/métabolisme , Protéine bcl-X/métabolisme , Antinéoplasiques/pharmacologie , Points de contrôle du cycle cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Cisplatine/pharmacologie , Sous-unité alpha 1 du facteur CBF/métabolisme , Humains , Facteur de transcription NF-kappa B/métabolisme , Phosphoprotein Phosphatases/génétique , Phosphorylation , Régions promotrices (génétique) , Protein phosphatase 2C , Facteur de transcription RelA/métabolisme , Protéine p53 suppresseur de tumeur/génétique , Protéine Bax/génétiqueRÉSUMÉ
The inactivation of the p53 tumor suppressor pathway in many cancers often increases their resistance to anticancer therapy. Here we show that a previously proposed strategy directed to Wip1 inhibition could be ineffective in tumors lacking p53. On the contrary, Wip1 overexpression sensitized these tumors to chemotherapeutic agents. This effect was mediated through interaction between Wip1 and RUNX2 that resulted, in response to anticancer treatment, in RUNX2-dependent transcriptional induction of the proapoptotic Bax protein. The potentiating effects of Wip1 overexpression on chemotherapeutic agents were directed only to tumor cells lacking p53. The overexpression of Wip1 in normal tissues provided protection from cisplatin-induced apoptosis through decreased strength of upstream signaling to p53. Thus, Wip1 phosphatase promotes apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.
Sujet(s)
Antinéoplasiques/pharmacologie , Sous-unité alpha 1 du facteur CBF/métabolisme , Régulation de l'expression des gènes tumoraux/physiologie , Tumeurs/traitement médicamenteux , Phosphoprotein Phosphatases/métabolisme , Protéine p53 suppresseur de tumeur/déficit , Animaux , Antinéoplasiques/métabolisme , Antinéoplasiques/usage thérapeutique , Apoptose/effets des médicaments et des substances chimiques , Apoptose/physiologie , Technique de Western , Lignée cellulaire , Amorces ADN/génétique , Synergie des médicaments , Femelle , Régulation de l'expression des gènes tumoraux/génétique , Humains , Immunohistochimie , Immunoprécipitation , Souris , Tumeurs/métabolisme , Plasmides/génétique , Protein phosphatase 2C , Réaction de polymérisation en chaine en temps réel , RT-PCR , Protéine p53 suppresseur de tumeur/métabolisme , Protéine Bax/métabolismeRÉSUMÉ
Degradation of Cdc25A phosphatase is an ubiquitous feature of stress. There are some discrepancies in the reported roles for different phosphorylation sites in the regulation of Cdc25A stability. Using a panel of doxycycline-inducible phosphorylation mutants we show that the stability of human Cdc25A protein is dependent upon phosphorylation at S75. In non-stressed conditions and in non-mitotic cells, Cdc25A is unstable and its stability is regulated in a Chk1-dependent manner. During mitosis, Cdc25A becomes stable and does not undergo degradation after DNA damage. We further show that Chk1 kinase regulates Cdc25A stability after UV irradiation. Similar to Chk1 kinase, p38 MAPK controls Cdc25A protein level after osmotic stress. Using phospho-specific antibodies, we find that both kinases can phosphorylate S75 and S123 in vitro. Inactivation of either Chk1 after UV-irradiation or p38 MAPK after osmotic stress prevents activation of a S phase checkpoint and S75 and S123 phosphorylation. However, introduction of stable Cdc25A (S75A or S75/123A) proteins is not sufficient to overcome this checkpoint. We propose that regulation of human Cdc25A stability by its phosphorylation at S75 may contribute to S phase checkpoint activation only in cooperation with other regulatory mechanisms.